PDF(Pubmed)
Abstract：
Granuloma annulare is a benign, inflammatory condition of unknown etiology, characterized by erythematous annular plaques, frequently on distal extremities. Generalized granuloma annulare can be difficult to treat, with varying success in therapeutic approaches. We present the case of a 59-year-old female with refractory generalized granuloma annulare successfully managed with adalimumab, requiring ongoing 40 mg q2weekly treatment for 2 years. While there are a handful of published case reports/series suggesting that adalimumab can be used to treat generalized granuloma annulare, dosing regimens and the need for long-term use remain inconsistent. This case adds further evidence for considering adalimumab as a sustained therapeutic option for recalcitrant generalized granuloma annulare. The patient responded to adalimumab, a tumor necrosis factor-alpha antagonist, administered biweekly for a year, then switched to weekly intervals. Most granuloma annulare lesions improved within 2 months and continued to improve throughout the treatment. Adalimumab may be proposed as a therapeutic treatment for recalcitrant forms of generalized granuloma annulare.
摘要：
环状肉芽肿是良性的,病因不明的炎症，以红斑环状斑块为特征，经常在四肢远端。广泛性环状肉芽肿很难治疗，在治疗方法上取得了不同的成功。我们介绍了一例59岁女性难治性环状肉芽肿成功治疗阿达木单抗，需要持续40mgq2每周治疗2年。虽然有少数已发表的病例报告/系列表明阿达木单抗可用于治疗广泛性环状肉芽肿，给药方案和长期使用的需要仍然不一致。该病例为阿达木单抗作为顽固性广泛性环状肉芽肿的持续治疗选择提供了进一步的证据。患者对阿达木单抗有反应，肿瘤坏死因子-α拮抗剂,为期一年，每两周一次，然后切换到每周间隔。大多数环状肉芽肿病变在2个月内得到改善，并在整个治疗过程中持续改善。阿达木单抗可能被提议作为难治性广泛性环状肉芽肿的治疗方法。
